GLP-1 Longevity: What a 17,000-Person Trial Just Showed Us

The 2024 SELECT trial randomized over 17,000 adults with overweight/obesity and pre-existing cardiovascular disease — none of whom had diabetes — to semaglutide 2.4 mg weekly or placebo. The primary outcome wasn't weight loss. It was major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death. The semaglutide group experienced a 20% relative reduction in MACE that was statistically separated from placebo within months and sustained over years. And the cardiovascular benefit was independent of the weight loss. That last sentence is the entire story. In this video, Dr. Trevor Turner — a board-certified PM&R physician and precision longevity practitioner at Pravida Health in Buckhead, Atlanta — walks through what the SELECT trial actually showed, why the cardiovascular and metabolic benefits appear to be independent of weight loss, and how this reframes the longevity case for GLP-1 receptor agonists in patients who aren't using them primarily for weight management. WHAT YOU'LL LEARN: 00:00 - Semaglutide: The First True Longevity Drug? 00:38 - Shifting the Conversation Beyond Weight Loss 01:06 - The SELECT Trial: Cardiovascular Risk Reduction 02:04 - What Semaglutide Does at the Cellular Level 02:23 - Mechanism 1: Cellular Senescence 02:38 - Mechanism 2: Mitochondrial Function 02:51 - Mechanism 3: Neuroinflammation & Stroke Risk 03:05 - Alzheimer’s & Epigenetic Aging Trials 03:40 - The Hidden Danger: Sarcopenic Obesity 04:23 - 3 Mandatory Rules Before Starting GLP-1s 04:59 - Case Study: Reversing Metabolic Dysfunction 05:42 - Precision Medicine at Pravida Health KEY TAKEAWAYS: • The SELECT trial enrolled 17,604 adults with cardiovascular disease and BMI ≥27 (no diabetes), randomized to semaglutide 2.4 mg/week vs. placebo • 20% relative reduction in major adverse cardiovascular events (MACE) — heart attack, stroke, cardiovascular death — over a mean follow-up of 39.8 months • Cardiovascular benefit was statistically independent of weight loss, separating the longevity case from the obesity case • Emerging signals suggest GLP-1s may reduce dementia risk and certain cancer incidences — but these are observational and require RCT confirmation • The honest tradeoff: GLP-1s cause meaningful loss of lean muscle mass and bone density when not paired with progressive resistance training and adequate protein intake • Patient candidacy for GLP-1 as a longevity intervention should include: comprehensive metabolic workup, body composition baseline (DEXA), and structured resistance training program in parallel • "Microdosing" GLP-1s is becoming a clinical practice with limited but growing evidence — appropriate for certain candidates, inappropriate for others • The current standard of care does not yet include GLP-1s as a routine longevity intervention, but the SELECT trial likely accelerates that conversation QUESTIONS TO ASK YOUR PHYSICIAN BEFORE STARTING GLP-1 THERAPY: • Has my candidacy been evaluated by metabolic markers (fasting insulin, HOMA-IR, ApoB) — not just BMI? • Do I have a body composition baseline (DEXA) before starting? • What is my resistance training plan to protect lean mass during therapy? • What protein intake am I targeting? (1.6-2.2 g/kg lean mass is the working clinical target) • How will we monitor for muscle loss and bone density changes over time? • What is my exit strategy when/if I stop therapy? ABOUT PRAVIDA HEALTH: Pravida Health is a precision longevity practice in Buckhead, Atlanta. Our GLP-1 therapy program includes comprehensive metabolic workup, baseline and longitudinal DEXA body composition tracking, structured resistance training prescription, protein optimization, and continuous glucose monitoring during therapy. We treat GLP-1s as one tool in a longevity protocol — not a standalone weight loss intervention. LEARN MORE: 🔗 Website: https://pravida.com 🔗 Membership tiers: https://pravida.com/memberships.html 🔗 GLP-1 consultation: https://pravida.com/contact.html 🔗 Read the blog: https://pravida.com/blog CONNECT WITH DR. TURNER: • Instagram: @pravidahealth • LinkedIn: Trevor Turner, MD REFERENCES: • Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. (SELECT trial) • Marso SP, et al. LEADER trial — liraglutide cardiovascular outcomes DISCLAIMER: This video is for educational purposes only and does not constitute medical advice. GLP-1 receptor agonists require physician evaluation and monitoring. Side effects, contraindications, and individual response vary. Always consult with a qualified physician about your specific case before starting any new medication. #GLP1 #Semaglutide #Tirzepatide #LongevityMedicine #SELECTtrial #Ozempic #Wegovy #Mounjaro #PravidaHealth #DrTrevorTurner